Prof Dimitrios P Bogdanos
@DBogdanos
Physician, autoimmunologist and Director, Rheumatology & Clin Immunology, Univ of Thessaly Med. School,,Greece Editor-in-Chief Autoimmunity Reviews,
You can always find something interesting to Read mjrheum.org/en_US/home
Check out the latest issue of MJR!! 🔹 Infrared Thermography in RMDs 🔹 Cortisol & RA outcomes 🔹 Anti-TIF1γ myositis 🔹 What do rheumatologists know about reproductive health? and much more!!
Check out the latest issue of MJR!! 🔹 Infrared Thermography in RMDs 🔹 Cortisol & RA outcomes 🔹 Anti-TIF1γ myositis 🔹 What do rheumatologists know about reproductive health? and much more!!
🧬 #SystemicSclerosis (SSc) shows a clear sex bias: A narrative review that discusses the issue in depth! #SystemicSclerosis #SSc #AutoimmuneDisease #SexDifferences #AutoimmuneResearch #Immunology #Fibrosis #LungDisease pubmed.ncbi.nlm.nih.gov/40423726/
🚨 New meta-analysis: Circulating follicular helper T (cTfh) cells are significantly increased in SLE patients, highlighting their role in disease development. Elevated cTfh may be promising biomarkers? 🔬🩺 #Autoimmunity #SLE #Immunology #Research sciencedirect.com/science/articl…
Indeed a unique opportunity to disseminate your research in rheumatology and have an impact!
The @MJR_journal is Platinum Access! This means no fees for submitting, processing and publishing your manuscript and all content access without a subscription! We are indexed in #Pubmed, #Scopus, #Embase, #WebofScience...and now we have an impact factor! mjrheum.org
🚀 Discover the Promising Role of GLP-1 Antagonists in Rheumatology: the pros and cons! A joint recent publication with Drs Bilgin and Venerito that I really enjoyed!
🚀🚀🚀🚀 ‼️‼️Fresh publication‼️‼️ 👉👉GLP-1 RAs are the hot topics of recent years. 👉👉They are promising effects in rheumatologic diseases. ⚠️Robust evidence is needed First of fruitful collaborations with @DBogdanos @vincevenerito @sakaryauni @ElsevierTurkiye
From the Editor-in-Chief: Autoimmunity Reviews maintains its strong performance with a new impact factor of 8.3, marking an unprecedented level of influence in the field of Autoimmunity Congratulations to all #AutoimmunityReviews #ImpactFactor #ResearchExcellence
The last lecture, of the last semester of the last year of our 6th year undergraduates of our Medical School. So proud of !!!! #MedicalStudents #ThessalyUniversity #MedicalEducation #FutureDoctors #MedSchoolLife #HealthScience #MedicalStudentsGreece #MedStudentLife #MedicalSchool
Probably the only Open Access Platinum (no publications fees), Pubmed Indexed Rheumatology Journal with an Impact Factor!!! Congratulations and next year even better!!1
🎉 Big milestone for the Mediterranean Journal of Rheumatology! We are proud to announce our first-ever Impact Factor: 1.4 (JCR 2024) 📊✨ This achievement reflects the dedication of our authors, reviewers, and editorial team — thank you for being part of this journey!
🎉 Big milestone for the Mediterranean Journal of Rheumatology! We are proud to announce our first-ever Impact Factor: 1.4 (JCR 2024) 📊✨ This achievement reflects the dedication of our authors, reviewers, and editorial team — thank you for being part of this journey!
With my good friends and co-patriots George Tsokos (Harvard) & Petros Sfikakis (Athens) at @eular_org Barcelona
With George (Tsokos) Harvard and Petros (Sfikakis) Athens at Barcelona
EULAR 2025 at Barcelona was a venue giving me the opportunity to make new friends and initiate new projects. With @dr_emrebilgin from Turkey
Barcelona's EULAR 2025 is close to the end! Approximately 7000 clinicians and scientists from all over the world celebrate the latest in Rheumatology
7/ 📄 Full study: Tsiogkas SG et al. Autoimmun Rev. 2025 Apr 21;24(6):103819. PMID: 40268128 doi.org/10.1016/j.autr… Thanks for reading! #RheumTwitter #MedTwitter #JAKinhibitors #PsA #SystematicReview
6/ ✨ Bottom line: ✅ Upadacitinib may offer clinical advantages in some PsA domains ⚠️ But more data are needed to fully assess long-term safety 🧠 Informed choices matter more than ever.
5/ 📈 Why this matters: Our study provides the first head-to-head evidence synthesis of current JAKi options in PsA. It highlights differential efficacy, but reminds us (to me): 🔍 One size doesn’t fit all. #PersonalizedMedicine #Autoimmunity
4/ ☣️ Safety? The rate of serious adverse events (SAEs) was comparable across JAKis, including upadacitinib. ➡️ No clear leader in safety, underscoring the need for individual risk–benefit decisions.
2/ ⚖️ Most JAKis outperformed placebo in all efficacy outcomes. However, upadacitinib stood out with statistical superiority in: ACR50 & ACR70, PASI75, dactylics ☣️ Safety? ... keep reading.
2/ 📚 We included randomized controlled trials from: MEDLINE CENTRAL Web of Science clinicaltrials.gov (up to Oct 2023) Outcomes: ACR20/50/70, PASI75, enthesitis/dactylitis resolution, HAQ-DI, and SAEs. #EvidenceBasedMedicine